-
Salix Pharmaceuticals, Ltd. SLXP today announced the
commencement of a cash tender offer by its indirect wholly owned
subsidiary, Willow Acquisition Sub Corporation (“Purchaser”), to
purchase all of the issued and outstanding shares of common stock, par
value $0.0001 per share, of Santarus, Inc. SNTS (“Santarus”) at
a purchase price of $32.00 per share, net to the seller in cash, without
interest and subject to any required withholding taxes. The tender offer
is being made pursuant to an Offer to Purchase, dated December 3, 2013,
and in connection with the previously announced definitive merger
agreement, dated November 7, 2013, among Salix, Salix Pharmaceuticals,
Inc., a wholly owned subsidiary of Salix (“Intermediary”), Purchaser and
Santarus.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in